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Abstract
A prospective, multicentre, phase IIIb study with an exploratory, open-label design was conducted to evaluate efficacy and safety of anidu-
lafungin for the treatment of candidaemia/invasive candidiasis (C/IC) in specific ICU patient populations. Adult ICU patients with con-
firmed C/IC meeting ‡1 of the following criteria were enrolled: post-abdominal surgery, solid tumour, renal/hepatic insufficiency, solid
organ transplant, neutropaenia, and age ‡65 years. Patients received anidulafungin (200 mg on day 1, 100 mg/day thereafter) for 10–
42 days, optionally followed by oral voriconazole/fluconazole. The primary efficacy endpoint was global (clinical and microbiological)
response at the end of all therapy (EOT). Secondary endpoints included global response at the end of intravenous therapy (EOIVT) and
at 2 and 6 weeks post-EOT, survival at day 90, and incidence of adverse events (AEs). The primary efficacy analysis was performed in the
modified intent-to-treat (MITT) population, excluding unknown/missing responses. The safety and MITT populations consisted of 216 and
170 patients, respectively. The most common pathogens were Candida albicans (55.9%), C. glabrata (14.7%) and C. parapsilosis (10.0%).
Global success was 69.5% (107/154; 95% CI, 61.6–76.6) at EOT, 70.7% (111/157) at EOIVT, 60.2% (77/128) at 2 weeks post-EOT, and
50.5% (55/109) at 6 weeks post-EOT. When unknown/missing responses were included as failures, the respective success rates were
62.9%, 65.3%, 45.3% and 32.4%. Survival at day 90 was 53.8%. Treatment-related AEs occurred in 33/216 (15.3%) patients, four (1.9%) of
whom had serious AEs. Anidulafungin was effective, safe and well tolerated for the treatment of C/IC in selected groups of ICU patients.
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Introduction
Invasive Candida infections have a particularly strong
impact on intensive care unit (ICU) patients [1], being
associated with mortality rates of 30–50% [1,2]. Fluconaz-
ole is generally effective for candidaemia/invasive candidia-
sis (C/IC), but its use may be hampered by a potential
increase in infections due to fluconazole-resistant Candida
spp. [3–5]. Recent guidelines favour echinocandins as first-
line therapy in haemodynamically unstable patients, those
with previous azole exposure, and clinical settings with
high local prevalence of fluconazole resistance [6–9].
However, the optimum therapy for C/IC in critically ill
patients is unknown.
ª2012 Pfizer Inc.
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases
ORIGINAL ARTICLE MYCOLOGY
Anidulafungin has excellent activity against invasive isolates
of Candida spp., including azole-resistant strains [10–12]. Anidu-
lafungin was shown to be more effective than fluconazole for
C/IC [13]; additional post hoc analyses seem to confirm its effi-
cacy in critically ill patients [14]. However, prospective data on
its use in this setting are lacking. Notably, less than half of all
patients enrolled in previous clinical trials of echinocandins for
C/IC were in the ICU at treatment initiation [14–16].
This exploratory, multicentre study prospectively evalu-
ated efficacy and safety of intravenous (IV) anidulafungin,
optionally followed by an oral azole, as first-line therapy for
confirmed C/IC in selected ICU patient populations across
Europe and Canada. The trial represents the first prospec-
tive assessment of an echinocandin for C/IC exclusively in
ICU patients, who comprise a major target population for
this antifungal class in clinical practice.
Methods
Study design
This was a phase IIIb, prospective, open-label, non-compara-
tive study in adult (‡18 years) ICU patients from ‡1 of the
following subpopulations: post-abdominal surgery, solid
tumour, renal insufficiency, hepatic insufficiency, solid organ
transplant, neutropaenia (neutrophil count < 500/mm3), and
age ‡65 years. Eligible patients had an Acute Physiology and
Chronic Health Evaluation II (APACHE II) score <25, signs
and symptoms of acute invasive fungal infection (IFI) within
48 h before starting study treatment, and confirmed C/IC
within 96 h before to 48 h after starting study treatment.
Patients who had received antifungals for £48 h before study
entry (one echinocandin dose maximum) without improve-
ment were eligible. Presence of renal/hepatic insufficiency
was determined by the investigator according to local guide-
lines. Patients with suspected Candida osteomyelitis, endocar-
ditis, meningitis and/or endophthalmitis were excluded.
The study was conducted in accordance with the Declara-
tion of Helsinki and Good Clinical Practice guidelines, and was
approved by all appropriate institutional review boards/ethics
committees. All patients or their legally authorized represen-
tatives were required to provide written informed consent.
Treatment
Patients received IV anidulafungin (200 mg on day 1, then
100 mg/day) for 10–42 days. Patients completing ‡10 days’
treatment could be switched to oral voriconazole or fluco-
nazole, provided they had two consecutive negative blood
cultures and resolution of IFI signs and symptoms. Azole
dosage was chosen according to local practice. Overall ther-
apy (with anidulafungin or step-down azole) was continued
for ‡14 days after the last positive blood/tissue culture and
resolution/significant improvement of IFI signs and symptoms.
The total maximum treatment duration was 56 days.
Endpoints
The primary endpoint was global response at end of all ther-
apy (EOT) in the modified intent-to-treat (MITT) population
(i.e. patients with confirmed C/IC at study entry who
received ‡1 anidulafungin dose). Global treatment success
was defined as both clinical and microbiological success (i.e.
cure/significant improvement of C/IC signs/symptoms and
eradication/presumed eradication of Candida spp). Presumed
eradication was defined as clinical success in the absence of
microbiological cultures. Global response was defined as
‘missing’ or ‘unknown’ in all patients with missing or
unknown clinical response, respectively, and any microbiolog-
ical response except failure. Clinical response was defined as
‘unknown’ in unevaluable patients (i.e. death (not caused by
C/IC), loss to follow-up, or received <3 anidulafungin doses).
Unless stated, missing or unknown responses were excluded
from analyses of global response. Secondary endpoints
included global response at end of IV therapy (EOIVT) and
at 2 and 6 weeks post-EOT, 90-day survival in the MITT
population, and incidence of adverse events (AEs) in the
safety population (i.e. patients who received ‡1 anidulafungin
dose). Candida scores were determined at study entry [17];
calculation of the colonization index (i.e. number of positive
sites/number of tested sites) was optional.
Statistical analyses
This study was exploratory. Success rates are presented as
number and percentage of patients with treatment success at
each time-point, with exact two-sided 95% confidence inter-
vals (CIs). Two-sided Z-tests were used to determine
whether the proportions of treatment successes were signifi-
cantly different between patients with and without baseline
C. albicans, candidaemia or septic shock, by baseline APACHE
II score (£20 vs. >20) or treatment pathway (oral step-down
therapy vs. anidulafungin alone), or by prompt intravascular
catheter removal. Survival to day 90 and day of first negative
blood culture were estimated using Kaplan-Meier methods.
Results
Patients and treatment
A total of 221 patients were screened at 61 sites across 19
countries (Appendix S1). The safety and MITT populations
comprised 216 and 170 patients, respectively (Fig. 1).
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Baseline demographics and clinical characteristics of the
MITT population are summarized in Table 1 and Appen-
dix S1. Notably, 41 (24.1%) patients were in septic shock.
Most patients had candidaemia only; the most common sites
for deep-tissue infection were peritoneal fluid, bile and pleu-
ral fluid (Appendix S1). Most MITT patients fell into >1 ICU
population at baseline: 34.1% patients were in two and 28.2%
in three or four. All 216 safety population patients received
concomitant drugs; commonly used co-medications were
anticoagulants, anti-inflammatory agents, antimicrobials, ben-
zodiazepines, diuretics, narcotic analgesics, proton-pump
inhibitors and vasopressors.
The predominant causative organism was C. albicans, fol-
lowed by C. glabrata and C. parapsilosis (Table 1). A total of
167 baseline isolates underwent susceptibility testing, and
most of these (n = 153) were fully susceptible to anidulafun-
gin, fluconazole and voriconazole (Appendix S1). At treat-
ment initiation, five MITT patients had a presumptive C/IC
diagnosis (confirmed within 48 h), while the remainder had
documented C/IC. In patients with candidaemia only, the
mean time between first positive blood culture and start of
anidulafungin therapy was 2.3 days.
The mean overall treatment duration in MITT patients
was 19.9 days (median, 18.5; range, 1–67), with a mean dura-
tion of anidulafungin therapy of 15.9 days (median, 14; range,
1–42). A total of 112 MITT patients (65.9%) received
anidulafungin only (mean duration, 16.2 days; range, 1–42),
while 44 (25.9%) were switched to oral fluconazole (mean
FIG. 1. Patient flowchart. aUntil end of study, which could range
from first day of study medication until 6 weeks after end of therapy
depending on the specific patient.
TABLE 1. Baseline demographics and clinical characteristics
of the modified intent-to-treat (MITT) population
Characteristic
MITT
population
(n = 170)
Demographic characteristics
Male, n (%) 101 (59.4%)
Mean age (range) 62.2 years
(25)89)
Race, n (%)
White 160 (94.1%)
Other (includes unspecified) 10 (5.9%)
Mean BMI (range)a 25.7 kg/m2
(15.4–83.0)
Risk factors for candidaemia/invasive candidiasis, n (%)
Broad-spectrum antibiotics 153 (90.0%)
Central venous catheter 148 (87.1%)
Prior surgery 113 (66.5%)
Total parenteral nutrition 99 (58.2%)
Dialysis/renal failure 59 (34.7%)
Systemic steroids or other
immunosuppressives/immunosuppressive
therapy
57 (33.5%)
Mucosal colonization by Candida species 52 (30.6%)
Chemotherapy 21 (12.4%)
Neutropaenia (neutrophil count <500/mm3) 13 (7.6%)
HIV infection 2 (1.2%)
Clinical characteristics
Post-abdominal surgery 90 (52.9%)
Elderly (‡65 years) 80 (47.1%)
Renal insufficiency/failure/dialysisb 67 (39.4%)
Solid tumour 45 (26.5%)
Hepatic insufficiencyb 27 (15.9%)
Neutropaenic 13 (7.6%)
Solid organ transplant recipient 10 (5.9%)
Infection site, n (%)
Blood only 114 (67.1%)
Other normally sterile site only 49 (28.8%)
Blood and other normally sterile site 7 (4.1%)
Mean Candida score (95% CI)c 3.4 (3.2–3.6)
Mean colonization index (95% CI)d 53.1 (45.7–60.6)
Mean SOFA score (95% CI)e 7.2 (6.6–7.9)
Septic shockf 41 (24.1%)
APACHE II score
£20 128 (75.3%)
>20 42 (24.7%)
Mean (range) 16.2 (4–26g)
Intravascular catheter status
All catheters removed/replacedh 40 (23.5%)
Not all catheters removed/replacedi 49 (28.8%)
No catheter inserted before
first positive culture
81 (47.6%)
Baseline pathogen
C. albicans 95 (55.9%)
C. glabrata 25 (14.7%)
C. parapsilosis 17 (10.0%)
C. tropicalis 13 (7.6%)
C. kefyr 3 (1.8%)
C. dubliniensis 2 (1.2%)
C. pelliculosa 2 (1.2%)
Other Candida spp.j 3 (1.8%)
Multiple Candida spp. 10 (5.9%)
APACHE II, Acute Physiology and Chronic Health Evaluation II; BMI, body mass
index; SOFA, Sequential Organ Failure Assessment.
aAssessed in n = 165 patients.
bThe presence/absence of these characteristics was determined by the local
investigator; there were no prespecified protocol definitions.
cAssessed in n = 167 patients.
dAssessed in n = 90 patients, expressed as a percentage.
eAssessed in n = 166 patients.
fDefined as having ‘severe sepsis’ (per the Candida score assessment) and a value
of 3 or 4 on the cardiovascular system component of the SOFA score.
gA single patient with a score ‡25 (i.e. 26) was included in the MITT population.
hPatients with ‡1 intravascular catheter inserted before the day of first positive
culture, all of which were removed or replaced by day 3 of anidulafungin ther-
apy.
iPatients with ‡1 intravascular catheters inserted before the day of first positive
culture, ‡1 of which had not been removed or replaced by day 3 of anidulafun-
gin therapy.
jOne each of C. krusei, C. lusitaniae and C. norvegensis.
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duration, 11.5 days; range, 1–44) and 14 (8.2%) to oral voric-
onazole (mean duration, 12.0 days; range, 4–30).
Efficacy
Global and microbiological success rates in the MITT popula-
tion are shown in Fig. 2. Global success at EOT was 69.5%
(107/154 patients; 95% CI, 61.6–76.6). If missing and
unknown responses among MITT patients (n = 170) were
treated as failures, global success rates decreased to 65.3%
(95% CI, 57.6–72.4) at EOIVT, 62.9% (95% CI, 55.2–70.2) at
EOT, 45.3% (95% CI, 37.7–53.1) at 2 weeks post-EOT, and
32.4% (95% CI, 25.4–39.9) at 6 weeks post-EOT.
No meaningful differences in global and microbiological
success rates were evident (Table 2) amongst most ICU
patient populations, with the possible exception of those
with neutropaenia (n = 12) and solid organ transplants
(n = 8), although the wide CIs in these populations limit the
interpretation of these findings. Success rates were not sig-
nificantly different in patients with and without candidaemia
and were similar in patients with and without C. albicans
(except for C. tropicalis). Global success rates throughout the
study were also similar in patients with baseline APACHE II
scores of £20 and >20 and in patients with or without septic
shock (Table 3). Global success rates were significantly
greater in patients receiving oral step-down therapy vs. those
receiving anidulafungin alone (Table 3). For patients with suc-
cessful global response at EOT, post-EOT success rates were
similar when given anidulafungin only vs. anidulafungin fol-
lowed by oral step-down therapy, at 2 (95.1% vs. 94.7%) and
6 weeks (89.7% vs. 87.1%). Global success at EOT in non-
neutropaenic patients (n = 142) was 71.1% (95% CI, 62.9–
78.4). In patients with intravascular catheters present before
day of first positive culture, global success rate at EOT was
higher for patients with all such catheters removed/replaced
by day 3 of anidulafungin treatment (77.1%; 95% CI, 59.9–
89.6) than otherwise (60.0%; 95% CI, 44.3–74.3), although
the difference was not statistically significant (p 0.10). First
negative blood culture was achieved by day 2 in >50% of
evaluable patients (Appendix S1).
FIG. 2. Global and microbiological success rates (with 95% confi-
dence intervals) in modified intent-to-treat patients at the end of
intravenous therapy (EOIVT), end of therapy (EOT), 2 weeks post
EOT and 6 weeks post EOT. Missing and unknown global or micro-
biological responses were excluded in these analyses. a95% confi-
dence interval (CI), 62.9–77.7. b95% CI, 66.4–80.5. c95% CI, 61.6–
76.6. d95% CI, 65.1–79.6. e95% CI, 51.1–68.7. f95% CI, 51.1–68.7.
g95% CI, 40.7–60.2. h95% CI, 40.7–60.2.
TABLE 2. Global and microbiological
success in modified intent-to-treat
patients at the end of therapy according
to specific ICU patient population and
baseline characteristics
Global success,
n (%) [95% CI]
Microbiologicl success,
n (%) [95% CI]
ICU patient population
Post-abdominal surgery 54/79 (68.4%) [56.9–78.4%] 55/80 (68.8%) [57.4–78.7%]
Elderly (‡65 years) 49/72 (68.1%) [56.0–78.6%] 54/75 (72.0%) [60.4–81.8%]
Renal insufficiency 44/58 (75.9%) [62.8–86.1%] 48/61 (78.7%) [66.3–88.1%]
Solid tumour 31/41 (75.6%) [59.7–87.6%] 32/42 (76.2%) [60.5–87.9%]
Hepatic insufficiency 18/25 (72.0%) [50.6–87.9%] 21/25 (84.0%) [63.9–95.5%]
Neutropaenic 6/12 (50.0%) [21.1–78.9%] 7/12 (58.3%) [27.7–84.8%]
Solid organ
transplant recipient
3/8 (37.5%) [8.5–75.5%] 4/8 (50.0%) [15.7–84.3%]
Baseline pathogena
C. albicansb 64/86 (74.4%) [63.9–83.2%] 69/89 (77.5%) [67.4–85.7%]
C. glabrata 15/22 (68.2%) [45.1–86.1%] 15/22 (68.2%) [45.1–86.1%]
C. parapsilosis 10/15 (66.7%) [38.4–88.2%] 11/15 (73.3%) [44.9–92.2%]
C. tropicalis 4/11 (36.4%) [10.9–69.2%] 6/12 (50.0%) [21.1–78.9%]
Any non-albicansb 37/58 (63.8%) [50.1–76.0%] 40/59 (67.8%) [54.4–79.4%]
Baseline infection site
Bloodc,d 73/108 (67.6%) [57.9–76.3%] 81/112 (72.3%) [63.1–80.4%]
Other normally
sterile site onlyd
34/46 (73.9%) [58.9–85.7%] 34/46 (73.9%) [58.9–85.7%]
Missing and unknown global or microbiological responses were excluded from these analyses.
aExcluding patients with multiple pathogens at baseline.
bThe differences between success rates in patients with C. albicans and non-albicans infections were not sta-
tistically significant (p 0.17 for global response, p 0.19 for microbiological response).
cIncludes patients with baseline infection site, either blood only or blood and other normally sterile site.
dThe differences between success rates in patients with candidaemia and without candidaemia were not sta-
tistically significant (p 0.44 for global response, p 0.84 for microbiological response).
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Safety and survival
Among the 216 patients in the safety population, 151 (69.9%)
received anidulafungin only; 49 (22.7%) and 16 (7.4%) also
received step-down therapy with fluconazole or voriconazole,
respectively. Treatment-related AEs occurred in 33/216
(15.3%) patients (total 80 events); most frequent were ery-
thema (n = 4, 1.9%), hypotension, increased blood alkaline
phosphatase, increased aspartate aminotransferase, diarrhoea
and atrial fibrillation (each n = 3, 1.4%). Most treatment-
related AEs were mild to moderate in severity (Appendix S1).
Furthermore, only 1.9% of patients experienced serious treat-
ment-related AEs (convulsions, n = 2; infusion-related AE,
n = 1; bronchospasm, n = 1). The types and frequency of AEs
were similar in the overall safety population and in patients
who received anidulafungin only (Appendix S1). Six patients
experienced ‡1 AE considered to potentially be infusion
related. Overall, five (2.3%) patients were permanently dis-
continued from the study due to ‡1 treatment-related AE.
The 60-day and 90-day survival estimates in the MITT
population were 58.0% (95% CI, 50.2–65.0) and 53.8% (95%
CI, 45.9–60.9; Appendix S1), respectively.
Discussion
This was the first prospective evaluation of therapy for C/IC
conducted specifically in ICU patients. This exploratory
non-comparative clinical trial confirmed the efficacy and
safety of anidulafungin for the treatment of documented C/
IC in selected adult ICU populations, many patients suffering
from multiple co-morbidities. The global success rate at EOT
was high (69.5%) and outcomes at this time-point were
mostly similar regardless of ICU population, causative patho-
gen, infection site or clinical factors (including APACHE II
score and septic shock status). Microbiological success rates
were similar to the respective global successes. The overall
incidence of treatment-related AEs (most were mild to mod-
erate) was low, suggesting excellent tolerability of anidulafun-
gin even in critically ill patients.
Published post hoc analyses of randomized clinical trials
showed lower or similar success rates at EOT with fluconaz-
ole (54%), conventional amphotericin B (69%), liposomal
amphotericin B (66%), micafungin (63%) and caspofungin
(68%) in ICU patients with C/IC [14–16]. A similar post hoc
analysis showed a 69% global success rate with anidulafungin
in ICU patients at EOIVT, compared with 76% in the overall
population of that study; both analyses treated missing and
unknown responses as therapeutic failures [13,14] while our
study excluded them from the primary endpoint. When
these cases were counted as failures, the EOIVT global suc-
cess rate in our study (65%) was almost identical to that
reported in the ICU post hoc analysis with anidulafungin [14].
Of note, mean APACHE II scores were somewhat higher in
the present study (16.2) than in the general C/IC population
(15.0) [13]. Patients with APACHE II scores ‡25 were
excluded from our trial, because the high crude mortality
rate in such patients would have impacted the evaluation of
drug efficacy; in patients with APACHE II scores >25 [18] or
even >20 [13,19], treatment differences are no longer
detectable. Exclusion of patients with high baseline scores is
likely to have contributed to similar responses regardless of
APACHE II score, contrary to what was observed in some
previous studies [18–20].
Treatment duration was longer than in prospective trials
assessing echinocandins for C/IC in general patient popula-
tions [13,19–21]; ICU patients may require longer durations
of antifungal treatment than non-ICU patients [22]. Our
results suggest that survival and global response rates in criti-
cally ill patients were lower at all time-points than previously
observed in a general population [13]. This is consistent with
other analyses indicating that ICU patients with invasive Can-
dida infections have higher mortality and worse outcomes
regardless of the antifungal agent used [14–16], probably
reflecting the worse underlying condition of this population.
ICU patients with systemic Candida infections should
therefore receive the most effective antifungal therapy avail-
able, as early as possible. Because the rapidly fungicidal action
TABLE 3. Global success rates over the course of the study
according to baseline APACHE II score, treatment strategy
and septic shock status in modified intent-to-treat patients
at the end of intravenous therapy (EOIVT), end of therapy
(EOT), 2 weeks post-EOT and 6 weeks post-EOT
EOIVT EOT
2 weeks
post-EOT
6 weeks
post-EOT
APACHE II £20a
n (%) 84/119 (70.6%) 80/116 (69.0%) 60/98 (61.2%) 44/84 (52.4%)
95% CI 61.5–78.6% 59.7–77.2% 50.8–70.9% 41.2–63.4%
APACHE II >20a
n (%) 27/38 (71.1%) 27/38 (71.1%) 17/30 (56.7%) 11/25 (44.0%)
95% CI 54.1–84.6% 54.1–84.6% 37.4–74.5% 24.4–65.1%
Switched to oral azolesb
n (%) 51/58 (87.9%) 47/55 (85.5%) 38/48 (79.2%) 29/41 (70.7%)
95% CI 76.7–95.0% 73.3–93.5% 65.0–89.5% 54.5–83.9%
IV anidulafungin onlyb
n (%) 60/99 (60.6%) 60/99 (60.6%) 39/80 (48.8%) 26/68 (38.2%)
95% CI 50.3–70.3% 50.3–70.3% 37.4–60.2% 26.7–50.8%
Septic shocka
n (%) 27/36 (75.0%) 25/34 (73.5%) 14/25 (56.0%) 10/22 (45.5%)
95% CI 57.8–87.9% 55.6–87.1% 34.9–75.6% 24.4–67.8%
No septic shocka
n (%) 84/121 (69.4%) 82/120 (68.3%) 63/103 (61.2%) 45/87 (51.7%)
95% CI 60.4–77.5% 59.2–76.5% 51.1–70.6% 40.8–62.6%
Missing and unknown global or microbiological responses were excluded from
these analyses.
aDifferences between global success rates were not statistically significant
(p > 0.05) at any time-point.
bDifferences between global success rates were statistically significant (p < 0.05)
at all time-points.
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of echinocandins may positively impact treatment outcomes
[23], these agents are now generally recommended as first-
line therapy for C/IC in moderately to severely ill patients
[8,9]. The results of our study support these clinical guide-
lines. Anidulafungin is the only echinocandin without dose
adjustment requirements for renal and hepatic impairment,
and with no known drug–drug interactions [24,25]. In our
trial, patients with hepatic and/or renal insufficiency (includ-
ing patients on dialysis) responded just as well as ICU
patients overall, further supporting the potential value of ani-
dulafungin in patients with organ dysfunction. Even though all
patients received concomitant medications, the tolerability of
anidulafungin was excellent.
Our study included a significant proportion (about one-
third) of C/IC patients with deep-tissue infection. This pro-
portion is considerably larger than in previous echinocandin
trials in C/IC, including post hoc analyses in ICU patients [13–
16,19–21], and supports the efficacy of anidulafungin for
treating invasive candidiasis as well as candidaemia. Also
noteworthy is that anidulafungin was just as effective against
C. parapsilosis as against other species. This particular patho-
gen has somewhat higher echinocandin minimum inhibitory
concentrations (MICs) than other Candida species, although
the clinical significance of these findings is unknown
[9,26,27]. The treatment response for C. tropicalis was lower
than for other Candida species and also lower than reported
previously with anidulafungin for C. tropicalis [13]. However,
our sample size for this subpopulation was small. The
observed species distribution matched what would be
expected from a pan-European study [28–31] and MICs were
similar to those reported previously [13].
Our results support the potential utility of the Candida
score for early diagnosis of C/IC in ICU patients, with scores
generally higher than the previously defined threshold of 2.5
[17]. This study also assessed the efficacy of de-escalation
therapy in critically ill populations (i.e. switching from an ech-
inocandin to oral azoles after resolution of clinical and
microbiological signs of infection). The higher global success
rates among patients receiving step-down therapy compared
with those receiving anidulafungin alone was expected,
because the study protocol dictated that only patients who
responded to IV therapy could switch to oral azoles. Nota-
bly, among patients with treatment success at EOT, response
rates were similar at later time-points regardless of the
treatment strategy, suggesting similar efficacy of both
approaches. Intravascular catheter removal by day 3 of ther-
apy did not significantly impact treatment response; because
indwelling catheters were not assessed for being a potential
source of infection, this particular result should be treated
with caution.
Our trial has several limitations. Due to the study design,
no direct comparison of anidulafungin with another antifungal
treatment is available. Furthermore, some of the specific sub-
groups comprised only a few patients, for example those
with solid organ transplants, neutropaenia and C. tropicalis
infections. The small sample sizes do not allow meaningful
conclusions to be drawn about these specific populations.
In conclusion, this is the first clinical trial to prospectively
evaluate an echinocandin in specific ICU populations, albeit
using an exploratory approach. The results demonstrate that
anidulafungin is an effective and safe treatment for confirmed
C/IC (including deep-tissue infection) in critically ill patients,
with success rates similar to those achieved with anidulafun-
gin in a general population. This efficacy appears to remain
consistent across certain high-risk patient groups, regardless
of a multitude of clinical factors and the causative pathogen.
Our observations support current guidelines [6–9] recom-
mending echinocandins as first-line therapy for the treatment
of C/IC in moderately to severely ill patients.
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